Guardant Health has received FDA approval for its next-generation liquid biopsy platform, Guardant360 Liquid CDx, expanding the role of blood-based genomic testing in cancers including non-small cell lung cancer and colorectal cancer.
The updated assay combines genomic and epigenomic profiling from a single blood draw and is designed to analyze a significantly broader molecular footprint than the company’s earlier test. According to Guardant, the platform can help identify actionable mutations for targeted therapies in NSCLC, colorectal cancer, and advanced breast cancer while delivering results within seven days.
The approval reflects the continued shift toward minimally invasive precision oncology diagnostics, where liquid biopsies are increasingly being used to guide treatment selection, especially when tissue samples are limited or difficult to obtain.